Oramed posted net income of $78.16 million, equal to $1.84 per diluted share, for the three months ended June 30, 2026.
Revenue was unchanged at no revenue, while operating loss widened 11% to $2.77 million.
Financial income climbed to $103.74 million on revaluation of investments in Alpha Tau; other income rose to $610,400.
Cash and cash equivalents fell to $15.25 million as of June 30, 2026; management expects funding to cover planned activities for 12 months.
Nano Dimension stake stood at 6,879,708 shares as of Aug. 10, 2026 following post-quarter sales; Oramed agreed to invest up to $1 million in MAR Oramed JV.
ORMP•
